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 Individual gene expression and personalised medicine in sepsis 
The results of many clinical trials on new sepsis 
therapies have been disappointing. Most of these 
studies have not shown any significant survival 
benefit in the heterogeneous patient populations 
included. The PROWESS study of the administration 
of activated protein C was the notable exception,1 and 
even resulted in the commercialisation of the drug. 
That is, until another placebo-controlled trial was 
conducted, and the results turned out to be entirely 
negative.2 Yet many experts (including me) believe 
that activated protein C can have beneficial effects 
in some patients,3 although identification of which 
patients could benefit is difficult in the absence of a 
reliable biomarker of sepsis. It might be possible to 
identify some genetic factors that could differentiate 
these patients,4 but this discovery arrived too late for 
activated protein C. 
Most sepsis drugs, including those targeting tumour 
necrosis factor α or interleukin 1, were developed 
to suppress the pro-inﬂ ammatory response. One of 
the reasons for the lack of success with these agents 
might be the fact that immunosuppression occurs 
early in patients with sepsis,5 so anti-inﬂ ammatory 
drugs will only be eﬀ ective if given very early. Indeed, 
as an example, it has been known for many years that 
interleukin 10, a typical anti-inﬂ ammatory cytokine, is 
released very early in sepsis.6
In The Lancet Respiratory Medicine, Emma Davenport 
and colleagues report novel ﬁ ndings about the 
immunological proﬁ le of patients with community-
acquired pneumonia-related sepsis.7 The investigators 
studied leucocyte global gene expression in patients 
admitted to 29 UK intensive care units (ICUs). Their 
prospective discovery cohort consisted of 265 patients 
and they validated their ﬁ ndings in a replication 
cohort of 106 patients. Using a sophisticated genomic 
analysis, Davenport and colleagues identiﬁ ed 
transcriptional sepsis response signatures (SRS). 
A type 1 SRS proﬁ le characterised patients with an 
immunosuppressed phenotype, which included 
endotoxin tolerance, T cell exhaustion, and human 
leucocyte antigen (HLA) class II downregulation. This 
phenotype, which was found in 108 (41%) patients 
in the discovery cohort, was associated with a 14-day 
mortality that was at least twice as high as that in the 
other patients (22% vs 10%, hazard ratio 2·4, 95% CI 
1·3–4·5, p=0·005). The investigators also propose a 
simpliﬁ ed  predictive set of seven genes that enabled 
classiﬁ cation of SRS. The study methodology is sound 
and the information provided in this Article7 could have 
important implications. 
First, more than 40% of the patients with 
community-acquired pneumonia in the discovery 
cohort had this immunosuppressive signature, and 
these patients also had a much worse outcome 
compared with the others. These numbers might not 
be very surprising to experts in this ﬁ eld, but could 
represent a blow to those who believe that anti-
inﬂ ammatory strategies are needed to treat sepsis. 
Second, the SRS proﬁ le was not related to the timing 
of sampling in relation to ICU admission. This result 
will challenge the simplistic view that an initial pro-
inﬂ ammatory response is followed later by an anti-
inﬂ ammatory response; the immunosuppressed 
pattern can actually occur very early. Third, patients 
with the immunosuppressed proﬁ le could not 
be identiﬁ ed by clinical assessment. This ﬁ nding 
clearly shows the importance of additional tests 
to complement the clinical examination. Nature 
produces more complex eﬀ ects than can be detected 
from clinical assessment alone. Wong and colleagues8 
have already shown that gene expression can be 
quite variable in children with septic shock, and 
might actually help to identify those who could 
beneﬁ t from—or be harmed by—corticosteroid 
administration. Pena and colleagues9 reported that 
an endotoxin tolerance signature was associated with 
the presence of sepsis and organ dysfunction. Finally, 
several possible immunostimulating interventions are 
being developed, including granulocyte macrophage 
colony-stimulating factor, interleukin 7, interleukin 
15, interferon γ, or co-inhibitory molecular blockade 
(eg, anti-programmed cell death receptor-1).10 The 
proposed simpliﬁ ed gene proﬁ le7 could help to identify 
those patients who might beneﬁ t from such novel 
immunostimulating strategies. Gene expression 
proﬁ ling could have other implications, including more 
rapid diagnosis of infections. Scicluna and colleagues11 
used blood microarray analysis to identify a 78-gene 
signature for community-acquired pneumonia. 
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In their abstract, Davenport and colleagues 
conclude: “Our ﬁ ndings provide new insights into 
the pathogenesis of sepsis and create opportunities 
for a precision medicine approach”.7 However, 
precision medicine might be too strong a term in 
this context; it is typically used to refer to the precise 
molecular targeting of therapeutic strategies. Perhaps 
personalised medicine would be more appropriate 
(ﬁ gure), although this is clearly not a new concept 
and one could argue that, as clinicians, we have 
always applied personalised medicine. Nevertheless, 
this approach is sometimes forgotten in the ﬁ eld of 
critical care medicine. All too often we have studied 
poorly characterised populations of patients grouped 
together as sepsis, acute respiratory distress syndrome, 
or even systemic inﬂ ammatory response syndrome, 
as if these entities were speciﬁ c disease states, but 
they are not. Over the years, this one-size-ﬁ ts-all 
approach has resulted in a multitude of negative 
randomised, controlled trials, especially in sepsis, with 
vast amounts of wasted eﬀ ort and resources. One 
size cannot ﬁ t all. The results of the current study by 
Davenport and colleagues, and other similar studies 
that provide a way to characterise patients with sepsis, 
will pave the way for researchers and, ultimately, 
clinicians to be able to target therapeutic strategies 
more appropriately and eﬀ ectively. This is certainly 
very good news. 
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Driving pressure and intraoperative protective ventilation
Since its invention as a supportive therapy, mechanical 
ventilation has been associated with detrimental 
eﬀ ects on pulmonary function even in healthy 
lun gs.1 During the past 40 years, these ﬁ ndings 
have led to novel pathophysiological concepts 
(eg, ventilator-induced lung injury, barotrauma, 
biotrauma, atelectrauma, and lung stress and strain) 
and ventilator strategies (eg, lung rest, open-lung 
approach, extra-corporeal CO2 removal), mainly 
used in the treatment of acute respiratory distress 
syndrome.2 The stigmatisation of the additive harmful 
eﬀ ect of mechanical ventilation reached its peak with 
ﬁ ndings of a reduced mortality associated with low 
tidal volume ventilation compared with conventional 
high tidal volume ventilation.3 Subsequently, driving 
pressure, which is the diﬀ erence between plateau 
airway and positive end-expiratory pressure, seems to 
be the best ventilator parameter with which to predict 
an increased risk of death associated with mechanical 
ventilation. 4
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